v1: 29 October 2024

Peer-approved: 29 October 2024

© The Author(s) 2024. This is an Open Access article under the CC BY 4.0 license.

Qeios, Vol. 6 (2024) ISSN: 2632-3834

Research Article

Thiazole Schiff Bases as Potential Breast Cancer Drugs Through Design, Synthesis, and In Silico Analysis

Maher Afroj Khanam¹, Ranajit Kumar Sutradhar¹, Ashutosh Nath², Mamiya Chowdhury³, Keya Rani Dutta¹, Sanjay Belowar⁴

1. Department of Chemistry, Chittagong University of Engineering and Technology, Bangladesh; 2. Department of Chemistry, University of Massachusetts Boston, Boston, United States; 3. Department of Chemistry, Dhaka University of Engineering and Technology, Bangladesh; 4. Department of Natural Science, BGMEA University of Fashion and Technology, Dhaka, Bangladesh

In this study, a series of thiazole-embedded Schiff base derivatives (TZ1-10) were investigated for their therapeutic potential against breast cancer, with TZ1-3 synthesized and TZ4-10 designed for comparative *in-silico* evaluation. Computational analyses, including Density Functional Theory (DFT) and molecular docking studies, revealed key electronic properties and binding affinities. The compounds exhibited HOMO-LUMO energy gaps indicating chemical stability, with TZ6 and TZ8 showing the most favorable values. ADMET profiling confirmed high bioavailability and low toxicity, with TZ6 and TZ8 showing ideal drug-likeness, positioning them as promising candidates for breast cancer therapeutics. Notably, TZ8 demonstrated a competitive binding affinity of -8.2 kcal/mol to the estrogen receptor (4FX3), comparable to FDA-approved drugs. These insights into stability, reactivity, and binding interactions provide a basis for future experimental validation, advancing the development of targeted cancer treatments with minimized adverse effects.

Correspondence: <u>papers@team.qeios.com</u> — Qeios will forward to the authors

1. Introduction

Breast cancer remains one of the most common malignancies globally, impacting millions of women annually and substantially contributing to cancer mortality rates. Although targeted therapies have enhanced treatment outcomes, resistance to these therapies remains a major challenge^{[1][2]}. Conventional treatments, such as chemotherapy, often cause severe side effects and may lead to tumor resistance, underscoring the need for novel, selective, and more effective anticancer agents^{[3][4]}. In response to these issues, research has increasingly focused on developing

small molecules with high specificity and minimal adverse effects.

Among various pharmacophores, Schiff bases and their derivatives have garnered significant interest in medicinal chemistry due to their structural versatility and potential bioactivity^{[5][6]}. Schiff bases, often derived from thiosemicarbazones, exhibit remarkable anticancer, antimicrobial, and antioxidant properties, making them suitable candidates for anticancer drug development^{[7][8][9]}. Thiazole-based Schiff bases, in particular, have shown considerable promise, as the thiazole moiety enhances molecular stability and facilitates effective interactions with biological targets, including proteins involved in cell cycle regulation and apoptosis^{[10][11][12][13]}.

Recent advancements in computational methods, such as Density Functional Theory (DFT) and molecular docking, enable the *in-silico* evaluation of compounds' stability, reactivity, and binding affinity, facilitating the preclinical assessment of drug candidates^{[14][15][16]} ^[17]. By applying these computational tools, it is possible to identify and optimize novel compounds for enhanced bioactivity and pharmacokinetic profiles before conducting *in vitro* or *in vivo* studies^{[18][19]}.

In this study, we synthesized and computationally assessed a series of thiazole-embedded Schiff base derivatives (TZ1-10) for their potential as breast cancer therapeutics. Compounds TZ1-3 were synthesized, and the entire series (TZ1-10) underwent in-silico analyses to evaluate their binding affinity to estrogen receptors, an important target in hormone-dependent breast cancer. examined Furthermore, we the compounds' pharmacokinetic properties to determine their druglikeness, bioavailability, and toxicity profiles. This research aims to identify promising lead compounds with the potential to serve as effective, safe, and accessible treatments for breast cancer, contributing to the development of targeted therapies with fewer side effects.

2. Materials and Methods

2.1. Materials

All starting materials and solvents used in the synthesis were procured from Sigma Aldrich and used without additional purification. The melting points of synthesized compounds were determined using an Electrothermal apparatus. Infrared spectra (IR) were measured using a SHIMADZU FTIR spectrophotometer (Model FTIR-IR Affinity-1) at the Wazed Miah Scientific Research Centre, Jahangirnagar University, Savar, Dhaka, to confirm the presence of functional groups like NH, C=N, and C=S. Nuclear Magnetic Resonance (NMR) spectra, including ¹H and ¹³C, were recorded using a BRUKER AVANCE III HD (400 MHz) spectrometer, with chemical shifts referenced in δ units to the residual protons in deuterated solvents. The spectral analyses for both IR and NMR were conducted at the Wazed Miah Science Research Centre, Jahangirnagar University, Bangladesh. These analyses facilitated the structural elucidation of the synthesized thiazole-embedded Schiff base derivatives.

2.2. Methods

2.2.1. General Procedure for the Preparation of Thiosemicarbazone Derivatives (4-6)

The synthesis of substituted thiosemicarbazone derivatives was conducted according to the method described by Al-Amiery^[20]. The reaction took place in an acidic medium, combining 0.01 mol of 4-substituted benzaldehyde (1) and 0.01 mol of thiosemicarbazide (2) in 20 mL of ethanol. This mixture was refluxed at 60 °C for 3 hours. After cooling to room temperature, the resulting-colored precipitate was filtered, washed with sodium bicarbonate solution, and recrystallized from 70% ethanol.

2.2.2. Synthesis of Thiazole-Embedded Schiff Base Derivatives (TZ1-TZ3)

A mixture of 0.013 mol of 3-chloroacetic acetone (3) and 0.015 mol of thiosemicarbazone derivatives (4-6) was dissolved in acetone and refluxed for 6 h. After completing the reaction, the crude mixture was cooled in an ice bath. The cooled mixture was then added to ice-cold water to induce precipitation. The precipitate was filtered and recrystallized from ethanol, with compounds TZ1-TZ3 subsequently purified via column chromatography. The reaction is shown in *Scheme 1*. All the reactions proceeded smoothly with diverse substituted thiosemicarbazone, and products were obtained in moderate yields. The structures of the synthesized compounds were elucidated by ¹H NMR, ¹³C NMR, DEPT, and HMBC spectroscopic methods.



Scheme 1. Synthesis of thiosemicarbazone scaffold and thiazole-embedded Schiff base derivatives. The reaction conditions are as follows: (i) Catalytic amount of HCl in EtOH, reflux for 3 h at 60-70°C, (ii) 3chloroacetyl acetone in acetone, reflux for 6 h.

Physical properties of 2-(4-(dimethylamino) benzylidene) hydrazine-1-carbothioamide, 4: Orange colored powder, Yield 90%, m. p. 210-212 °C, IR (KBr, cm⁻¹, 5): 3406,3251(w, NH₂), 3051(C-H, Ar), 1593.99(C=N), 1184.29 (C=S), 815.85 (C-S-C). ¹HNMR (400 MHz, DMSO-d₆, δ ppm, 5): 7.59 (1H, d, J= 8.8 Hz, H-2'); 6.71 (1H, d, J= 8.4 Hz, H-3');6.71 (1H, d, J= 8.4 Hz, H-5') and 7.59 (1 H, d, J= 8.8 Hz, H-6'); 7.98 (1H, s, CH=N);3.36 (1H, s);11.04 (2H, s); 2.95 (2H, s). ¹³C NMR (400 MHz, DMSO-d₆, δ ppm, 5): 121.8(C1'), 129.0(C2'), 112.1(C3'), 151.8(C4'), 112.1(C5'), 129.0(C6'), 143.8 (CH=N), 177.4(C=S),40.2N (CH₃)₂.

Physical properties of 2-(4-chlorobenzylidene) hydrazine-1-carbothioamide, 5: Brown coloured crystal, Yield 93%, m. p. 222-225 °C, IR (KBr, cm⁻¹, 6): 3468,3360(w, NH₂), 1587.47(C=N), 1234.44 (C=S), 877.46 (C-S-C). ¹HNMR (400 MHz, DMSO-d₆, δ ppm, 6): 7.59 (1H, d, J= 8.8 Hz, H-2'); 6.71 (1H, d, J= 8.4 Hz, H-3');6.71 (1H, d, J= 8.4 Hz, H-5') and 7.59 (1 H, d, J= 8.8 Hz, H-6'); 7.98 (1H, s, CH=N);3.36 (3H, s);2.95(2H, s). ¹³C NMR (400 MHz, DMSO-d₆, δ ppm, 6): 125.5(C1'), 129.9(C2'), 116.0(C3'), 159.7(C4'), 116.0(C5'), 129.5 (C6'),143.2(CH=N), 177.8(C=S).

Physical properties of (E)-2-(4-hydroxybenzylidene) hydrazine-1-carbothioamide, 6: White powder, Yield 75%, m. p. 213 ~ 215 °C, IR (KBr, cm⁻¹, 7): 3560,3150.40(NH₂), 1612.40 (C=N), 1275.02 (C=S), 844.82 (C-S-C). ¹HNMR (400 MHz, DMSO-d₆, δ ppm, 7): 7.59 (1H, d, J= 8.8 Hz, H-2'); 6.71 (1H, d, J= 8.4 Hz, H-3'); 6.71 (1H, d, J= 8.4 Hz, H-5') and 7.59 (1 H, d, J= 8.8 Hz, H-6'); 7.98 (1H, s, CH=N); 3.36 (3H, s); 2.95(2H, s). ¹³C NMR (400 MHz, DMSO-d₆, δ ppm, 7): 133.0(C1'), 129.4(C2'), 129.1(C3'), 134.7(C4'), 129.1(C5'), 129.4 (C6), 141.0(<u>C</u>H=N), 178.5(<u>C</u>=S).

Physical properties of 1-(2-(2-(4-(dimethylamino) benzylidene) hydrazineyl)-4-methylthiazol-5-yl) ethan-1one, TZ1: Brown powder, Yield 55%, m.p.228-230 °C, IR (KBr, cm⁻¹, TZ1): 3160 (NH), 3070 (w, C-H, Ar), 1604.77 (C=O), 1525.60 (C=N),1300.67, 1178.51 (C=S). ¹HNMR (400 MHz, DMSO-d₆, δ ppm, TZ1: 7.50 (1H, d, J= 8.4 Hz, H-2'); 6.75 (1H, d, J= 8.4 Hz, H-3');6.75 (1H, d, J= 8.4 Hz, H-5'); 7.50 (1H, d, J= 8.4 Hz, H-6'); 7.98 (1H, s, CH=N);3.38 (s);2.95(s). ¹³C NMR (400 MHz, DMSO-d₆, δ ppm, TZ1: 121.7(C1'), 129.0(C2'), 112.1(C3'), 151.9(C4'), 112.3(C5'), 129.0(C6'), 146.3(CH=N), 169.3(C=S), 111.5(C2''), 128.5(C4''), 189.0(C=O), 29.9(COCH₃), 18.7(4''-<u>C</u>H₃), 40.2N(<u>C</u>H₃)₂.

Physical properties of 1-(2-(2-(4-chlorobenzylidene) hydrazineyl)-4-methylthiazol-5-yl) ethan-1-one, TZ2: Light brown colored crystal, Yield 55%, m.p.190~192°C, IR (KBr, cm⁻¹, TZ2): 3560, 3150 (NH), 3014.74, 2926 (w, C-H, Ar), 1612.40 (C=O), 1512.19 (C=N),1275.02 (C=S).¹HNMR (400 MHz, DMSO-d₆, δ ppm, TZ2): 2.51(s, 3H, CO-CH₃), 2.41(s, 3H, H-4'), 7.55 (d,1H, H-2', J = 8.4 Hz), 6.86 (d, 1H, H-3', J = 8.4 Hz), 6.86 (d,1H, H-5', J = 8.4 Hz) and 7.55 (d,1H, H-5', J = 8.4 Hz), 8.11 (s, 1H, CH=N). ¹³C NMR (400 MHz, DMSO-d₆, δ ppm, TZ2): 125.1(C1'), 129.2(C2'), 116.2(C3'), 160.1(C4'), 116.2(C5'), 129.2(C6'), 147.0(<u>C</u>H=N), 168.8(<u>C</u>=S), 122.0(C2"), 154.6(C4"), 189.3(C=O), 29.9(CO<u>C</u>H₃), 17.9(4"-<u>C</u>H₃).

Physical properties of 1-(2-(2-(4-hydroxybenzylidene) hydrazineyl)-4-methylthiazol-5-yl) ethan-1-one, TZ3: White colored powder, Yield 55%, m.p. 242-244°C, IR (KBr, cm⁻¹, TZ3): 3414 (w, OH Ar),2738, 2645 (NH), 1622 (C=O), 1494 (C=N), 1240 (C=S). ¹HNMR (400 MHz, DMSOd₆, δ ppm, TZ3): 2.41(s, 3H, H-4'), 2.51(s, 3H, CO-CH₃), 5.38 (s,1H, NH), 7.72 (d,1H, H-2', J = 8.0Hz), 7.51(d, 1H, H-3', J = 8.4Hz), 7.51 (d,1H, H-5', J = 8.4Hz), 7.72 (d,1H, H-6', J = 8.0Hz), 8.16 (s,1H, HO-4' and CH=N). ¹³C NMR (DMSO-d₆, 400 MHz) δ : 133.0(C1'), 129.4(C2'), 129.1(C3'), 134.7(C4'), 129.1(C5'), 129.4 (C6), 141.0(<u>C</u>H=N), 178.5(<u>C</u>=S).

2.2.3. Computational methods

1. DFT Calculation

The structural properties of thiazole derivatives were modified and optimized using Gaussian $09^{[21]}$ W Revision D.01. Visualization was carried out using Gauss View 6.0.16^[21] software. Density Functional Theory (DFT) with the B3LYP functional and 6-311++G (d, p) basis set was applied to calculate spectral and physicochemical properties in the gas phase. Vibrational frequencies were confirmed to match minima on the potential energy surface, and molecular orbital characteristics were analyzed to assess chemical reactivity^[19].

2. Thiazole Derivatives (TZ) Optimization, Protein Preparation, and Molecular Docking

Gauss View 6.0.16 was utilized to prepare the Gaussian input files (.gif) for Thiazole derivatives (TZ1-10). Each structure was optimized using Gaussian 09 and the B3LYP method. Protein structures were obtained from the RCSB Protein Data Bank (PDB). The specific proteins used were Homo sapiens Spodoptera frugiperda (PDB ID: 4FX3)^[22] Homo sapiens Peptide from Nuclear receptor corepressor 2 (protein), Progesterone receptor (protein) (4OAR)^[23] Homo sapiens Cell division protein kinase 6 (protein) (3NUP)^[24] and Homo sapiens Escherichia coli (3ERT)^[25] Prior to docking, water molecules were removed, and original ligands were extracted. Ligands were docked against proteins using Autodock Vina^[26] on the $PyRx^{[27]}$ workstation, with the grid box positioned around the macromolecule's active site. Visualization of receptor-ligand binding interactions was performed using Biovia Discovery Studio^[28] 2024 Client.

3. Analysis of Drug Likeness of TZ1-10

Toxicity and pharmacokinetic properties were assessed using the updated AdmetSAR version 2.0^[28] (http://lmmd.ecust.edu.cn/admetSAR2/). Druglike properties of the compounds TZ (1-10) were Molinspiration analyzed using the online server^[29] (https://www.molinspiration.com/cgibin/properties).

3. Result and Discussion

3.1. Chemistry

The structures of the synthesized compounds (TZ1-3), along with the designed compounds (TZ4-10), are shown in Figure 1. The spectral data of the synthesized thiazole-embedded Schiff base derivatives TZ1-TZ3 confirmed their structures through IR, ¹H NMR, and ¹³C NMR spectroscopy. In the IR spectra, TZ1 showed absorptions at 3160 cm⁻¹ for NH, 1604.77 cm⁻¹ for C=O, and 1525.60 cm⁻¹ for C=N^[30]. For TZ2, peaks at 3560 and 3150 cm⁻¹ corresponded to NH, with C=O and C=N absorptions at 1612.40 and 1512.19 cm⁻¹, respectively^[31]. TZ3 exhibited a hydroxyl (-OH) group absorption at 3414 cm⁻¹, alongside C=O and C=N peaks at 1622 and 1494 cm^{-1[31][32][33][34]}. In ¹H NMR, characteristic singlet signals for CH=N were observed at around 7.98 ppm (TZ1 and TZ2) and 8.16 ppm (TZ3), confirming the Schiff base linkage^[35]. ¹³C NMR spectra further validated these structures, with characteristic C=N signals appearing between 141.0 and 147.0 ppm and C=O peaks ranging from 169.3 to 189.0 ppm^[36]. This data collectively verifies the successful synthesis of the desired Schiff base compounds.



Figure 1. Designed new structures of thiazole derivatives

3.2. In-silico Study of Thiazole-Embedded Schiff Base Derivatives and Frontier Molecular Orbital Analysis

We designed ten Schiff base derivatives for further insilico study, as illustrated in Figure 1. The optimized structures, shown in Figure S2, were calculated using Gaussian 09 W software, employing density functional theory (DFT) for optimization. Frontier molecular orbital (FMO) analysis was conducted to assess the Highest Occupied Molecular Orbital (HOMO) and the Lowest Unoccupied Molecular Orbital (LUMO), which play a crucial role in determining chemical reactivity. The HOMO reflects the ability of a molecule to donate electrons, while the LUMO indicates its capacity to accept electrons. The energy difference between these orbitals ($\Delta E = E_{LUMO} - E_{HOMO}$) is a key parameter for understanding the stability and reactivity of the compounds.

Table 1 presents the calculated values for E_{HOMO} , E_{LUMO} , and the energy gap (ΔE) for compounds TZ1-10. The HOMO energy values (E_{HOMO}) range from -0.17413 to -0.25362, indicating the highest occupied molecular orbitals. The LUMO energy values (E_{LUMO}) span from -0.05563 to -0.19278, representing the energy levels of the lowest unoccupied orbitals, where more negative LUMO values suggest a greater ability to accept electrons. The HOMO-LUMO energy map is provided in Figure S1.

The HOMO-LUMO energy gap (ΔE) ranges from 0.02533 to 0.14029, with larger gaps indicating increased

molecular stability. The hardness (η), representing the resistance to deformation of the electron cloud, shows positive values between 0.01267 and 0.07015. Softness (σ), which is inversely related to hardness, varies from 14.2572 to 78.9578, suggesting that compounds with higher softness may exhibit higher reactivity.

Electronegativity (μ) values range from -0.13966 to -0.2332, with more negative values indicating stronger electron-attracting tendencies. Chemical potential (χ) values, closely linked to electronegativity, vary from 0.11488 to 0.2232. Lastly, electronophilicity (ω) values, which are very low (0.111371 to 1.487589), suggest that these compounds have a limited tendency to accept electrons.

TZs	E _{HOMO}	E _{LUMO}	ΔΕ	η	σ	μ	χ	ω
TZ1	-0.17413	-0.05563	0.1185	0.05925	16.8776	-0.11488	0.11488	0.111371
TZ2	-0.21524	-0.07496	0.14028	0.07014	14.2572	-0.1451	0.1451	0.150086
TZ3	-0.20127	-0.06098	0.14029	0.07015	14.2562	-0.13113	0.131125	0.122559
TZ4	-0.21783	-0.11970	0.09813	0.04907	20.3811	-0.16877	0.168765	0.290244
TZ5	-0.25362	-0.19278	0.06084	0.03042	32.8731	-0.2232	0.2232	0.81884
TZ6	-0.20678	-0.18145	0.02533	0.01267	78.9578	-0.19412	0.194115	1.487589
TZ7	-0.23287	-0.13715	0.09572	0.04786	20.8943	-0.18501	0.18501	0.357592
TZ8	-0.23464	-0.11653	0.11811	0.05906	16.9334	-0.17559	0.175585	0.261029
TZ9	-0.24895	-0.14713	0.10182	0.05091	19.6425	-0.19804	0.19804	0.385188
TZ10	-0.19957	-0.07974	0.11983	0.05992	16.6903	-0.13966	0.139655	0.16276

Table 1. Chemical reactivity of TZ1-10

N.B.: global hardness (η), chemical potential (μ), softness (σ), electronegativity (χ), global electrophilicity index (ω).

3.3. Drug-likeness and Pharmacokinetic Characteristics

The molecular properties of TZ compounds, such as bioavailability and membrane permeability, are influenced by key factors like partition coefficient (logP), molecular weight (MW), and the number of hydrogen bond donors and acceptors, following Lipinski's "rule of five." As shown in Table 2, the molecular weight (MW) of these compounds ranges from 275.33 to 339.40 g/mol. Most of the TZ derivatives comply with Lipinski's rule, which applies to compounds with a molecular weight of less than 500 g/mol. The number of rotatable bonds ranges from four to six, where fewer rotatable bonds are often linked to

improved bioavailability. The hydrogen bond properties show that most compounds have around six donors and one or two acceptors, both of which are crucial for solubility and receptor interactions. The Topological Polar Surface Area (TPSA) values range from 82.59 Å² to 145.34 $Å^2$, with lower TPSA (below 140 $Å^2$) generally associated with better permeability and absorption, though TZ6 may have slightly reduced absorption. The consensus Log P values, indicating hydrophobicity, range from 1.71 to 3.30, with values between 1 and 3 typically showing optimal permeability and solubility. Notably, TZ2 presents no Lipinski violations, shows low skin permeability (-5.29), has an excellent Log P (3.30), and a low molecular weight. TZ10 also stands out with no violations, an ideal Log P (2.99), and a low TPSA (121.39 Å²), while TZ9 exhibits good bioavailability due to its moderate Log P (2.54), acceptable molecular weight, and low TPSA.

TZ Derivatives	MW (g/mol)	Num rotatable bonds	Num H bonds acceptors	Num H bond donors	TPSA (A2)	Consensus Log Po/w	Log Kp(skin permeation) cm/s	Lipinski rule	Violation
TZ1	302.40	5	6	1	85.83	2.79	-5.70	Yes	0
TZ2	293.78	4	5	1	82.59	3.30	-5.29	Yes	0
TZ3	275.33	4	6	2	102.82	2.35	-5.87	Yes	0
TZ4	289.36	6	6	1	91.82	2.78	-5.73	Yes	0
TZ5	303.34	5	6	2	119.89	2.34	-6.13	Yes	0
TZ6	339.40	5	7	2	145.34	1.71	-6.90	Yes	0
TZ7	289.36	5	6	2	102.82	2.30	-6.34	Yes	0
TZ8	302.36	5	6	2	125.68	1.92	-6.58	Yes	0
TZ9	284.34	4	6	1	106.38	2.54	-5.88	Yes	0
TZ10	291.40	4	6	2	121.39	2.99	-5.61	Yes	0

Table 2. ADME properties of TZ derivatives

Bioactivity score of TZ 1-10

The bioactivity scores of TZ compounds 1–10 were assessed. The drug-likeness of the lead compounds was evaluated using Molinspiration (https://www.molinspiration.com/cgi/properties), incorporating a range of factors, including GPCR

modulators, ion channel modulators, kinase inhibitors, nuclear receptor ligands, protease inhibitors, and enzyme inhibitors (see Table 3). These combinations were analyzed to identify compounds suitable for further drug development. The bioactivity scores provide insights into the binding profiles of the compounds, which are useful in designing new drugs with improved selectivity and fewer side effects. Among the compounds, TZ6 displayed the fewest negative scores, suggesting higher overall bioactivity, particularly in its ability to bind GPCRs (-0.56) and inhibit enzymes (-0.28). TZ7 also demonstrated moderate activity, especially as a protease inhibitor (-1.08) and kinase inhibitor (-0.81).

Drug	GPCR ligand	Ion channel modulator	Kinase inhibitor	Nuclear receptor ligand	Protease inhibitor	Enzyme inhibitor
TZ1	- 0.73	- 1.20	- 0.77	- 1.12	- 1.16	- 0.49
TZ2	- 0.90	- 1.29	- 1.00	- 1.38	- 1.39	- 0.58
TZ3	- 0.84	- 1.23	- 0.93	- 1.17	- 1.32	- 0.47
TZ4	- 0.86	- 1.31	- 0.93	- 1.25	- 1.29	- 0.56
TZ5	- 0.72	- 1.17	- 0.85	- 0.96	- 1.09	- 0.40
TZ6	- 0.56	- 1.02	- 0.88	- 1.34	- 0.81	- 0.28
TZ7	- 0.70	- 1.11	- 0.81	- 1.08	- 1.03	- 0.34
TZ8	- 0.72	- 1.25	- 0.67	- 1.27	- 1.03	- 0.43
TZ9	- 0.79	- 1.22	- 0.76	- 1.11	- 1.21	- 0.44
TZ10	- 0.96	- 1.47	- 1.14	- 1.53	- 1.25	- 0.49

Table 3. Bioactivity score of TZ 1-10

3.4. Molecular Docking

3.4.1. Protein selection

Molecular docking is instrumental in drug discovery as it identifies potential therapeutic candidates, enhances the efficacy of existing medications, and elucidates the molecular basis of biological processes. This study selected proteins 4FX3, 4OAR, 3NUP, and 3ERT for their critical roles in hormone-dependent breast cancer and inflammation. Estrogen receptor alpha (4FX3) and aromatase (4OAR) are key in hormone signaling and cancer cell proliferation, making them vital for evaluating anti-cancer compounds. Nuclear Factorkappa B (3NUP) regulates inflammation and cancer progression, while estrogen receptor beta (3ERT) is involved in apoptosis and hormone signaling. The thiazole-embedded Schiff base derivatives, particularly TZ6 and TZ8, demonstrated high binding affinities with these proteins, indicating potential as anti-cancer and anti-inflammatory agents. This targeted approach enhances the understanding of these compounds' therapeutic potential and guides further optimization for clinical applications. Table 5 shows that the TZ derivatives (TZ1-10) exhibit excellent docking performance, interacting with significant amino acids. Docking 55 complexes of four proteins with eleven TZ derivatives revealed specific protein targets related to the biological activity of the TZ drugs. TZ9 and TZ8 showed the highest affinities, indicating moderate interaction levels. Compounds like TZ2, TZ7, and TZ8 had strong interactions with the 3NUP receptor, highlighting its significance in the substance's mechanism of action. TZ9 and TZ8 also showed significant affinities, underscoring this receptor as crucial for the bioactivity of TZ drugs.

PDB ID	Functions
4FX3	Phosphorylation of proteins involved in the G2, M transition by Cyclin A:Cdc2 complexes, cyclin A2-CDK1 complex, cell cycle G1/S phase transition, cellular response to cocaine, Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
40AR	glandular epithelial cell maturation, Loss of MECP2 binding ability to the NCoR/SMRT complex, negative regulation of androgen receptor signaling pathway, tertiary branching involved in mammary gland duct morphogenesis
3NUP	Multivesicular body, internal vesicle lumen, negative regulation of cardiocyte differentiation, positive regulation of protein kinase C activity, Shc-EGFR complex, epidermal growth factor receptor activity
3ERT	G protein-coupled estrogen receptor activity, regulation of epithelial cell apoptotic process, antral ovarian follicle growth, regulation of branching involved in prostate gland morphogenesis,

Table 4. Protein functions

Compound/Docking score (k/cal)	4FX3	40AR	3NUP	3ERT
TZ1	-6.7	-7.3	-7.0	-6.6
TZ2	-7.8	-7.7	-7.6	-6.5
TZ3	-7.6	-7.6	-7.2	-6.8
TZ4	-7.4	-7.6	-6.6	-6.6
TZ5	-7.9	-7.4	-6.8	-7.6
TZ6	-8.0	-7.6	-6.8	-7.1
TZ7	-7.7	-7.6	-6.5	-7.1
TZ8	-8.2	-7.5	-7.0	-7.3
TZ9	-7.9	-7.8	-6.4	-7.4
TZ10	-7.2	-6.7	-6.3	-6.5

 Table 5. Molecular Docking scores of selected TZ1-10 compounds with the four receptors.

In Table 6, derivatives TZ8 and TZ6 demonstrated the highest binding affinities towards the 4FX3 receptor, with docking scores (S) of -8.2 and -8.0 kcal/mol, respectively. The derivative TZ8 formed three hydrogen bonds with LEU83 at distances of 1.95 Å, 2.25 Å, and 2.11 Å, and three hydrogen bonds with PHE82. Derivative TZ6 exhibited the formation of five hydrogen bonds involving LYS33, ASP86, LEU83, GLN85, with distances

of 2.46 Å, 2.10 Å, 2.47 Å, 2.79 Å, and 2.83 Å, respectively. However, TZ5 and TZ9 displayed different interactions with 4FX3 despite having identical binding affinities. TZ5 established five hydrogen bonds with LEU83, LYS33, and GLN85, at distances of 2.35 Å, 2.67 Å, 2.16 Å, 2.73 Å, and 2.60 Å, respectively. TZ9 formed two hydrogen bonds with LEU83 and PHE82 at distances of 1.20 Å and 2.77 Å.

FDA approved drugs	4FX3	40AR	3NUP	3ERT
Anastrozole	-8.1	-6.8	-8.2	-7.9
Doxorubicin	-8.5	-8.3	-8.4	-7.8
Gemcitabine	-7.6	-6.7	-6.6	-7.3
Tamoxifen	-5.7	-8.5	-6.2	-5.7

Table 6. Molecular Docking score of FDA approval drug

FDA-approved drugs generally exhibit stronger binding affinities, with Doxorubicin and Tamoxifen displaying the lowest energy values (-8.4 and -8.5 kcal/mol, respectively). Among the TZ compounds, TZ8 shows the strongest binding with the 4FX3 receptor (-8.2 kcal/mol), which is comparable to the binding strength of Doxorubicin. The binding affinities of FDA-approved medications range from -5.7 to -8.5 kcal/mol. Compared to these medications, the TZ compounds demonstrate slightly weaker binding strengths, ranging from -6.3 to -8.2 kcal/mol. FDA-approved medications generally exhibit greater and more consistent binding across receptors compared to the TZ1-10 compounds. This suggests that while FDA-approved medications may be more efficient, the TZ compounds-notably TZ8-still show competitive binding, particularly with 4FX3. These findings indicate the potential for further optimization of TZ compounds to enhance their binding affinities to levels comparable to or exceeding those of FDA-approved medications.



Figure 2. (a) 2D Interaction of TZ6 + 4fx3 complex. (b) 2D Interaction of TZ8 + 4fx3 complex.









Figure 4 illustrates the crucial role of electron-donating and electron-withdrawing groups in modulating the antibacterial activity of a thiazole-based compound. The figure demonstrates the impact of substituents on the antibacterial properties of the compound, highlighting the significance of these groups in controlling biological activity. At the core of the figure is a thiazole ring structure, renowned for its biological relevance in numerous medicinal compounds. The basic structure being studied consists of an aryl group and an acetyl group attached to the thiazole ring. The letter "X" marks a position on the aryl ring where various substituents can be introduced, significantly altering the compound's antibacterial action.

Figure 4 reveals that antimicrobial activity against the 4OAR strain is enhanced by the introduction of electron-donating groups such as dimethylamino $(N(CH_3)_2)$, methoxy (MeO), and hydroxy (OH) at the X position. These groups increase the electron density of the ring, potentially improving the compound's efficacy by strengthening its interaction with microbial enzymes or cell membranes. Conversely, electron-withdrawing groups like cyano (CN), amide (CONH₂), sulfonic acid (SO₂OH), carboxylic acid (COOH), and chloride (Cl) enhance antibacterial activity against the 4FX3 strain. These groups decrease the electron density of the ring, which may heighten the molecule's binding affinity to microbial targets and boost its antibacterial activity.

Moreover, the figure clearly shows that modifying the substituents at the X position can fine-tune the antibacterial activity of the thiazole-based molecule. The distinct roles of electron-donating and electron-withdrawing groups in targeting different bacterial strains provide a strategic approach to developing more effective antimicrobial drugs.

4. Conclusion

In contrast to four FDA-approved breast cancer medicines, this study focuses on the synthesis and insilico assessment of ten new thiazole-embedded Schiff base derivatives (TZ1-10). Notably, TZ6 and TZ8 demonstrated noteworthy docking scores above -6 kcal/mol, as well as excellent oral bioavailability and encouraging ADME characteristics. These substances showed low toxicity and no carcinogenic qualities, as well as substantial binding affinities, especially towards the 4FX3 protein. According to the knowledge gained from this study, TZ6 and TZ8 have a great deal of promise as anticancer drugs. In order to increase these compounds' binding affinities and boost their therapeutic efficacy, future research will concentrate on improving their molecular structure. Furthermore, to validate these computational predictions and evaluate the complete pharmacological potential of these derivatives, in-vitro and in-vivo investigations are required. These initiatives may eventually aid in the creation of fresh, more focused, and efficient therapies for breast cancer, providing a substitute for the current ones, which frequently have unfavorable side effects and resistance.

Statements and Declarations

Conflict of Interests

The authors declare no competing financial interests.

Acknowledgments

We are grateful to the Chittagong University of Engineering and Technology (CUET), Chattogram, Bangladesh, for all kinds of experimental and financial support.

References

- [△]Hameed A, Al-Rashida M, Uroos M, Abid Ali S, Khan KM. Schiff bases in medicinal chemistry: a patent revi ew (2010-2015). Expert opinion on therapeutic patents 2017; 27(1): 63-79.
- △Bharti S, Nath G, Tilak R, Singh S. Synthesis, anti-bact erial and anti-fungal activities of some novel Schiff ba ses containing 2, 4-disubstituted thiazole ring. Europe an journal of medicinal chemistry 2010; 45(2): 651-66 0.
- 3. [△]Docherty JH, Lister TM, Mcarthur G, Findlay MT, Do mingo-Legarda P, Kenyon J, Choudhary S, Larrosa I. T ransition-metal-catalyzed C–H bond activation for th e formation of C–C bonds in complex molecules. Che mical Reviews 2023; 123(12): 7692-7760.
- ^AMushtaq I, Ahmad M, Saleem M, Ahmed A. Pharmac eutical significance of Schiff bases: An overview. Futur e Journal of Pharmaceutical Sciences 2024; 10(1): 16.
- 5. [△]Teran R, Guevara R, Mora J, Dobronski L, Barreiro-Co sta O, Beske T, Pérez-Barrera J, Araya-Maturana R, Roj as-Silva P, Poveda A. Characterization of antimicrobia l, antioxidant, and leishmanicidal activities of Schiff b ase derivatives of 4-aminoantipyrine. Molecules 2019; 24(15): 2696.
- 6. [△]Çakmak R, Ay B, Çınar E, Başaran E, Akkoç S, Boğa M, Taş E. Synthesis, spectroscopic, thermal analysis an d in vitro cytotoxicity, anticholinesterase and antioxid ant activities of new Co (II), Ni (II), Cu (II), Zn (II), and Ru (III) complexes of pyrazolone-based Schiff base lig and. Journal of Molecular Structure 2023; 1292: 13622 5.
- 7. [△]Kostova I, Saso L. Advances in research of Schiff-base metal complexes as potent antioxidants. Current medi cinal chemistry 2013; 20(36): 4609–4632.

- ^AEl-Lateef HMA, El-Dabea T, Khalaf MM, Abu-Dief A M. Recent overview of potent antioxidant activity of c oordination compounds. Antioxidants 2023; 12(2): 213.
- 9. △Pisanu F, Sykula A, Sciortino G, Maseras F, Lodyga-C hruscinska E, Garribba E. Experimental and Computat ional Studies on the Interaction of DNA with Hespereti n Schiff Base CuII Complexes. International journal of molecular sciences 2024; 25(10): 5283.
- 10. [△]Oladipo SD, Luckay RC, Olofinsan KA, Obakachi VA, Z amisa SJ, Adeleke AA, Badeji AA, Ogundare SA, George BP. Antidiabetes and antioxidant potential of Schiff ba ses derived from 2-naphthaldehye and substituted aro matic amines: Synthesis, crystal structure, Hirshfeld su rface analysis, computational, and invitro studies. Heli yon 2024; 10(1).
- ^AArshad MF, Alam A, Alshammari AA, Alhazza MB, Al zimam IM, Alam MA, Mustafa G, Ansari MS, Alotaibi AM, Alotaibi AA. Thiazole: A versatile standalone moi ety contributing to the development of various drugs and biologically active agents. Molecules 2022; 27(13): 3994.
- [△]Petrou A, Fesatidou M, Geronikaki A. Thiazole ring— A biologically active scaffold. Molecules 2021; 26(11): 3 166.
- 13. [△]Rani M, Nath A, Kumer A. In-silico investigations on t he anticancer activity of selected 2-aryloxazoline deri vatives against breast cancer. Journal of Biomolecular Structure and Dynamics 2023; 41(17): 8392-8401.
- 14. [△]Choi JE, Kim Z, Park CS, Park EH, Lee SB, Lee SK, Choi YJ, Han J, Jung KW, Kim HJ. Breast cancer statistics in K orea, 2019. Journal of Breast Cancer 2023; 26(3): 207.
- 15. [△]Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Imm unotherapy and targeted therapy combinations in me tastatic breast cancer. The lancet oncology 2019; 20(3): e175-e186.
- 16. [△]Xia Y, Sun M, Huang H, Jin WL. Drug repurposing for cancer therapy. Signal Transduction and Targeted The rapy 2024; 9(1): 92.
- 17. [△]Nath A, Kumer A, Zaben F, Khan MW. Investigating t he binding affinity, molecular dynamics, and ADMET properties of 2, 3-dihydrobenzofuran derivatives as a n inhibitor of fungi, bacteria, and virus protein. Beni-S uef University Journal of Basic and Applied Sciences 2 021; 10(1): 36.
- ^ASarkar M, Nath A, Kumer A, Mallik C, Akter F, Moniru zzaman M, Ali MA. Synthesis, molecular docking scree ning, ADMET and dynamics studies of synthesized 4-(4-methoxyphenyl)-8-methyl-3, 4, 5, 6, 7, 8-hexahydro quinazolin-2 (1H)-one and quinazolinone derivatives. Journal of Molecular Structure 2021; 1244: 130953.

- 19. ^{a, b}Nath A, Kumer A, Khan MW. Synthesis, computatio nal and molecular docking study of some 2, 3-dihydro benzofuran and its derivatives. Journal of Molecular S tructure 2021; 1224: 129225.
- 20. [△]Al-Amiery A, Isahak WNRW, Al-Azzawi WK. Multi-m ethod evaluation of a 2-(1, 3, 4-thiadiazole-2-yl) pyrrol idine corrosion inhibitor for mild steel in HCl: combini ng gravimetric, electrochemical, and DFT approaches. Scientific Reports 2023; 13(1): 9770.
- 21. ^{a, b}Caricato M, Frisch MJ, Hiscocks J, Frisch MJ. Gaussia n 09: IOps Reference; Gaussian Wallingford, CT, USA, 2 009.
- 22. [△]Li C, Xie Y, Hu S, Yu H, Xu Y, Shen H, Yuan Y, Gu L, Pu B. Identification of formononetin as the active compo und of CR-SR in hepatocellular carcinoma treatment: An integrated approach combining network pharmac ology and weighted gene co-expression networks. Che mical Biology & Drug Design 2024; 103(1): e14363.
- 23. [△]Kitete Mulongo E, Kilembe Thambwe J, Matondo A, Ngbolua K-T-N, Tshilanda D, Mungu Yvette N-U, Tshib angu D, Tshimankinda Mpiana P. The Potential of Co mpounds Derived from Jatropha Curcas Against Pr an d Herα in Breast Cancer Treatment: Molecular Dockin g and Molecular Dynamics Simulation Studies.
- 24. [△]Jiang C, Ye Y, Kang W, Yang J, He Z, Cao Q, Lian C, Xin g Y, Yang Q, Zhao J. Elucidating Binding Selectivity in C yclin-Dependent Kinases (CDKs) 4, 6, and 9: Developm ent of Highly Potent and Selective CDK4/9 Inhibitors. 2024.
- 25. [△]Somturk-Yilmaz B, Turkmenoglu B, Akkoc S. Synthes is, Characterization, Cytotoxic Activity Studies of N1-p henylbenzene-1, 2-diamine@ CuhNFs and 1, 2-phenyl enediamine@ CuhNFs, and Molecular Docking Calcul ations of Their Ligands. Journal of Inorganic and Orga nometallic Polymers and Materials 2024; 1-13.
- 26. [△]Trott O, Olson AJ. AutoDock Vina: improving the spee d and accuracy of docking with a new scoring functio n, efficient optimization, and multithreading. Journal of computational chemistry 2010; 31(2): 455-461.
- 27. [△]Dallakyan S, Olson AJ. Small-molecule library screeni ng by docking with PyRx. Chemical biology: methods and protocols 2015; 243-250.
- 28. ^{a, b}Jejurikar BL, Rohane SH. Drug designing in discove ry studio. 2021.
- 29. [△]Suganya M, Jose Kavitha S, Raja Kannan V. Insilco St udies of Molecular Property and Bioactivity of Organi c Crystalline Compounds using Molinspiration. Intern ational Research Journal of Engineering and Technolo gy 2020.
- 30. [^]Preethi V, Vijukumar V, AnilaRaj S, Vidya V. Synthesis, characterization, DFT studies and evaluation of the po

tential anti-tumour activity of nicotinic hydrazide bas ed Schiff base using in vitro and molecular docking tec hniques. Heliyon 2024; 10(9).

- 31. ^{a, b}Belowar S, Rahamatolla M, Islam S, Jalil MA, Hossa in S, Saeed MA, Bhuiyan MMR, Kazi F, Shekh S. Desig n, synthesis, and characterization of a novel pH-respo nsive azo dye incorporating a 1, 3, 4-thiadiazole ring f or advanced textile applications. Dyes and Pigments. 2024; 231: 112410.
- 32. [△]Kheirkhahi M, Shaabani B, Samadi Kafil H. Calix [4] arene-based thiosemicarbazide Schiff-base ligand an d its transition metal complexes: synthesis and biologi cal assessment. Journal of the Iranian Chemical Societ y. 2021; 18(12): 3429-3441.
- 33. ^AEmam SM, Bondock S, Aldaloa AA. Schiff base coordi nation compounds including thiosemicarbazide deriv

ative and 4-benzoyl-1, 3-diphenyl-5-pyrazolone: Synt hesis, structural spectral characterization and biologic al activity. Results in Chemistry. 2023; 5: 100725.

- 34. [△]Nehar OK, Mahboub R, Louhibi S, Roisnel T, Aissaoui M. New thiosemicarbazone Schiff base ligands: Synth esis, characterization, catecholase study and hemolyti c activity. Journal of Molecular Structure. 2020; 1204: 1 27566.
- 35. [△]Berber N. Preparation and characterization of some Schiff base compounds. Adıyaman University Journal of Science. 2020; 10(1): 179–188.
- 36. ^ΔBonnel C, Legrand B, Bantignies J-L, Petitjean H, Mar tinez J, Masurier N, Maillard LT. FT-IR and NMR struct ural markers for thiazole-based γ-peptide foldamers. Organic & Biomolecular Chemistry. 2016; 14(37): 8664 -8669.

Supplementary data: available at https://doi.org/10.32388/8M92BF.2

Declarations

Funding: No specific funding was received for this work. **Potential competing interests:** No potential competing interests to declare.